Keryx Biopharmaceuticals (KERX) +45.4% premarket on news its Zerenex experimental kidney disease...

|About: Keryx Biopharmaceuticals, Inc. (KERX)|By:, SA News Editor

Keryx Biopharmaceuticals (KERX) +45.4% premarket on news its Zerenex experimental kidney disease drug had met its late-stage trial goal of reducing phosphate levels in blood. KERX expects to submit a new drug application with the FDA and a marketing authorization application with the EMA for Zerenex in Q2.